SABS - SAB Biotherapeutics, Inc. Stock Price, Fair Value and News

4.02USD-0.08 (-1.95%)Market Closed

Market Summary

USD4.02-0.08

Market Closed

-1.95%

SABS Stock Price

View Fullscreen

SABS RSI Chart

SABS Valuation

Market Cap

37.1M

Price/Earnings (Trailing)

-0.88

Price/Sales (Trailing)

16.56

EV/EBITDA

0.51

Price/Free Cashflow

-1.46

SABS Price/Sales (Trailing)

SABS Profitability

EBT Margin

-1884.50%

Return on Equity

-73.64%

Return on Assets

-50.27%

Free Cashflow Yield

-68.26%

SABS Fundamentals

SABS Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

-85.88%

Rev. Growth (Qtr)

-75.93%

SABS Earnings

Earnings (TTM)

-42.2M

Earnings Growth (Yr)

-190.26%

Earnings Growth (Qtr)

-347.97%

Breaking Down SABS Revenue

Last 7 days

0.3%

Last 30 days

-10.7%

Last 90 days

-32.6%

How does SABS drawdown profile look like?

SABS Financial Health

Current Ratio

5.45

Debt/Equity

0.01

Debt/Cashflow

-46.38

SABS Investor Care

Buy Backs (1Y)

81.69%

Diluted EPS (TTM)

-11.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	12.7M	6.4M	4.1M	2.2M
2022	55.8M	43.9M	32.8M	23.9M
2021	56.6M	58.1M	59.5M	60.9M
2020	0	0	29.3M	55.2M
2019	0	0	0	3.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of SAB Biotherapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 07, 2023	sullivan eddie joe	bought	1,531	0.88	1,740	chief executive officer
Nov 30, 2023	king michael	bought	4,500	0.9	5,000	chief financial officer
Nov 29, 2023	reich samuel j	bought	9,841	0.8947	11,000	executive chairman
Nov 24, 2023	ellias helen k.	acquired	-	-	2,857,140	-
Nov 24, 2023	moin andrew	acquired	-	-	4,584,570	-
Nov 24, 2023	sessa capital (master), l.p.	acquired	-	-	4,584,570	-
Mar 14, 2023	kropotova alexandra	acquired	-	-	275,000	chief medical officer
Dec 07, 2022	hamilton christine e	acquired	99,999	1.205	82,987	-
Dec 07, 2022	link david charles	acquired	49,999	1.205	41,493	-
Dec 07, 2022	spragens jeffrey g	acquired	99,999	1.205	82,987	-

Which funds bought or sold SABS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	Princeton Global Asset Management LLC	new	-	2,270	2,270	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	sold off	-100	-9,000	-	-%
Apr 26, 2024	Nadler Financial Group, Inc.	sold off	-100	-9,453	-	-%
Apr 12, 2024	First PREMIER Bank	sold off	-100	-555,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.96	69,370	684,841	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	sold off	-100	-315	-	-%
Feb 14, 2024	Sessa Capital IM, L.P.	new	-	3,151,890	3,151,890	0.10%

Are Funds Buying or Selling SABS?

Are funds buying SABS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SABS

No. of Funds

Unveiling SAB Biotherapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	radcliffe capital management, l.p.	0.00%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.99%	9,220,672	SC 13G
Feb 14, 2024	commodore capital lp	3.5%	1,831,746	SC 13G/A
Dec 04, 2023	biotechnology value fund l p	5.3%	4,896,104	SC 13G
Oct 16, 2023	commodore capital lp	9.9%	6,932,463	SC 13G

Recent SEC filings of SAB Biotherapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 29, 2024	8-K	Current Report
Mar 08, 2024	8-K	Current Report
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to SAB Biotherapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

SAB Biotherapeutics, Inc. News

Latest updates

SAB Biotherapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	-75.9%	305,011	1,267,361	85,518	581,101	2,160,872	3,589,708	6,350,525	11,803,077	11,058,253	14,680,589	18,209,502	16,927,734	-	-	-
Operating Expenses	191.0%	19,178,782	6,590,283	6,562,136	7,983,110	10,020,885	11,397,024	12,893,469	18,510,416	18,402,485	18,670,943	21,082,043	16,113,810	8,996	-	-
S&GA Expenses	478.9%	14,881,346	2,570,565	2,900,006	3,447,389	2,863,449	4,044,046	4,309,042	5,186,072	7,754,567	3,600,678	2,398,641	3,331,806	-	-	-
R&D Expenses	6.9%	4,297,436	4,019,718	3,662,130	4,535,721	7,157,436	7,352,978	8,584,427	13,324,344	10,647,918	15,070,265	18,683,402	12,782,004	-	-	-
EBITDA Margin	-200.9%	-17.07	-5.67	-3.94	-1.84	-0.64	-0.59	-0.38	-0.27	-0.25	0.35	0.36	0.37	0.38	-	-
Interest Expenses	11.7%	77,879	69,700	75,320	92,385	87,699	70,626	71,237	72,022	66,275	78,558	74,434	75,192	-	-	-
Income Taxes	-	-	-	-	-	-	-	-92,281	92,281	-	-	-	-	-	-	-
Earnings Before Taxes	-348.0%	-22,856,763	-5,102,317	-6,880,886	-7,353,820	-7,848,970	-7,076,068	-4,868,277	1,078,144	-11,551,496	-4,061,190	-2,941,679	1,409,834	-	-	-
EBT Margin	-183.9%	-18.84	-6.64	-4.54	-2.14	-0.78	-0.68	-0.44	-0.31	-0.28	0.34	0.35	0.36	0.36	-	-
Net Income	-348.0%	-22,856,763	-5,102,317	-6,880,886	-7,353,820	-7,874,599	-7,076,068	-4,775,996	985,863	-11,551,496	-4,061,190	-2,941,679	1,409,834	-8,996	-	-
Net Income Margin	-183.6%	-18.84	-6.65	-4.55	-2.14	-0.78	-0.68	-0.44	-0.32	-0.28	-0.09	0.35	0.36	0.36	-0.31	-
Free Cashflow	-157.3%	-13,514,581	-5,253,121	-4,921,840	-1,627,017	-1,672,778	-7,997,224	-5,060,874	-10,895,049	-7,240,091	569,315	-9,849,347	7,563,339	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	196.2%	84.00	28.00	35.00	43.00	51.00	53.00	59.00	68.00	81.00	51.00	117	117	57.00	18.00
Current Assets	1783.4%	59.00	3.00	9.00	15.00	22.00	22.00	28.00	37.00	50.00	22.00	1.00	1.00	34.00	9.00
Cash Equivalents	2232.2%	57.00	2.00	8.00	13.00	15.00	8.00	17.00	22.00	33.00	11.00	10.00	20.00	13.00	6.00
Net PPE	-4.3%	20.00	21.00	22.00	22.00	23.00	24.00	25.00	25.00	24.00	23.00	-	-	15.00	3.00
Liabilities	103.7%	27.00	13.00	16.00	18.00	20.00	22.00	22.00	27.00	43.00	16.00	10.00	8.00	18.00	10.00
Current Liabilities	17.4%	11.00	9.00	11.00	14.00	15.00	17.00	16.00	19.00	26.00	10.00	0.00	0.00	11.00	5.00
Long Term Debt	-	-	-	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	275.6%	57.00	15.00	20.00	24.00	31.00	31.00	37.00	41.00	39.00	35.00	38.00	41.00	39.00	8.00
Retained Earnings	-34.1%	-90.10	-67.21	-62.10	-55.20	-47.87	-40.00	-32.92	-28.14	-29.13	-17.58	-8.96	-6.76	-11.98	-32.10
Additional Paid-In Capital	73.7%	153	88.00	87.00	85.00	84.00	76.00	76.00	75.00	68.00	53.00	4.00	-2.04	51.00	30.00
Shares Outstanding	-82.4%	9.00	52.00	52.00	50.00	5.00	43.00	43.00	43.00	43.00	26.00	26.00	26.00	26.00	-
Float	-	-	-	31.00	-	-	-	33.00	-	-	-	115	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-160.2%	-13,446	-5,167	-4,899	-1,605	-1,555	-7,918	-4,448	-9,537	-4,878	3,797	-6,385	9,453	-10.03	-	-
Share Based Compensation	-16.0%	537	639	645	603	629	578	570	898	651	881	433	349	-	-	-
Cashflow From Investing	-66.1%	-67.86	-40.86	-22.68	-21.30	-117	-78.50	-612	-1,280	-2,361	-3,228	-3,463	-1,890	-	-	-
Cashflow From Financing	48306.1%	67,637	-140	-363	-359	8,387	-287	-731	-6,317	36,034	-51.23	-46.23	-45.47	95.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SABS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenue	$ 2,238,991	$ 23,904,181
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Grant Revenue [Member]	Grant Revenue [Member]
Operating Expenses [Abstract]
Research and Development Expense	$ 16,515,005	$ 36,438,513
General and Administrative Expense	23,799,306	16,383,285
Total operating expenses	40,314,311	52,821,798
Loss from operations	(38,075,320)	(28,917,617)
Changes in fair value of warrant liabilities	(4,823,237)	10,399,200
Interest expense	(315,284)	(301,584)
Interest income	584,966	71,072
Other income	435,089	33,754
Total other income (expense)	(4,118,466)	10,202,442
Loss before income taxes	(42,193,786)	(18,715,175)
Income tax expense (benefit)	0	25,629
Net loss	(42,193,786)	(18,740,804)
Other comprehensive loss:
Foreign currency translation	26,420
Total comprehensive loss	$ (42,167,366)	$ (18,740,804)
Loss per common share attributable to the Company's shareholders
Basic loss per common share	$ (7.64)	$ (4.31)
Diluted loss per common share	$ (7.64)	$ (4.31)
Weighted-average common shares outstanding - Basic	5,521,487	4,352,497
Weighted-average common shares outstanding - diluted	5,521,487	4,352,497

SABS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 56,566,066	$ 15,046,894
Accounts receivable, net	0	5,556,577
Prepaid expenses and other current assets	2,340,797	1,493,982
Total current assets	58,906,863	22,097,453
Long-term prepaid insurance	350,230	467,694
Operating lease right-of-use assets	1,277,982	1,192,054
Financing lease right-of-use assets	3,669,659	3,896,873
Property, plant and equipment net	19,736,519	23,250,853
Total assets	83,941,253	50,904,927
Current liabilities
Accounts payable	945,927	3,679,116
Notes payable	1,050,849	772,665
Operating lease liabilities, current portion	669,946	490,794
Finance lease liabilities, current portion	132,004	132,788
Deferred grant income	1,322,410	0
Accounts Payable and Other Accrued Liabilities, Current	6,692,181	9,917,981
Total current liabilities	10,813,317	14,993,344
Operating lease liabilities, noncurrent	635,777	361,225
Finance lease liabilities, noncurrent	3,418,483	3,629,642
Warrant liabilities	11,774,235	320,930
Notes payable, noncurrent	0	541,644
Total liabilities	26,641,812	19,846,785
Commitments and contingencies (Note 17)
Stockholders' equity
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 42,236 shares issued and outstanding at December 31, 2023 and 0 shares issued and outstanding at December 31, 2022, respectively	5
Common stock; $0.0001 par value; 800,000,000 shares authorized at December 31, 2023 and December 31, 2022; 9,280,159 and 5,094,901 shares issued, respectively, and 9,225,494 and 5,040,236 outstanding at December 31, 2023 and December 31, 2022, respectively	929	510
Treasury stock, at cost; 54,665 shares held at December 31, 2023 and 2022	(5,521,246)	(5,521,246)
Additional paid-in-capital	152,856,874	84,448,633
Accumulated other comprehensive income	26,420
Accumulated deficit	(90,063,541)	(47,869,755)
Total stockholders' equity	57,299,441	31,058,142
Total liabilities and stockholders equity	$ 83,941,253	$ 50,904,927

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

CEO	Dr. Eddie Joe Sullivan Ph.D.
WEBSITE	sabbiotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	56

SAB Biotherapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for SAB Biotherapeutics, Inc.? What does SABS stand for in stocks?

SABS is the stock ticker symbol of SAB Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SAB Biotherapeutics, Inc. (SABS)?

As of Thu May 02 2024, market cap of SAB Biotherapeutics, Inc. is 37.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SABS stock?

You can check SABS's fair value in chart for subscribers.

What is the fair value of SABS stock?

You can check SABS's fair value in chart for subscribers. The fair value of SAB Biotherapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SAB Biotherapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SABS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SAB Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether SABS is over valued or under valued. Whether SAB Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact SAB Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SABS.

What is SAB Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, SABS's PE ratio (Price to Earnings) is -0.88 and Price to Sales (PS) ratio is 16.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SABS PE ratio will change depending on the future growth rate expectations of investors.